Gene therapy shows early promise against deadly brain cancer

June 1, 2015 by Alan Mozes, Healthday Reporter
Gene therapy shows early promise against deadly brain cancer
DNA-modified virus serves as decoy to help target and destroy glioblastoma cells, researchers say.

(HealthDay)—Early trials of a new form of gene therapy may give hope to patients battling glioblastoma, the most deadly form of brain cancer.

Called AdV-Tk therapy, the new treatment involves two steps. As the researchers explained it, the first step involves taking DNA from the herpes virus and injecting it into , and then attacking those DNA-tagged cells with a powerful drug.

In the second step, the drug helps spur the patient's immune systems to eliminate more of the cancer cells over time.

All of the patients in the study had also undergone surgeries aimed at minimizing the tumor, the researchers noted.

The result, so far, has been a marked improvement in prognosis for the 48 patients participating in the preliminary trial.

"Glioblastoma is the most you can have," said study co-author Dr. David Baskin, professor of neurosurgery with both Houston Methodist Hospital and the Weill-Cornell College of Medicine in New York City. "It's almost always a death sentence, with median survival of about nine to 15 months, and the quality of life during the last five months is often quite poor.

"Surgery, along with chemotherapy and radiation, is the only current treatment option," he added. "This cancer is like an octopus—it reaches into all parts of the brain [and] you can only ever get some of it out."

However, "this particular gene therapy is better than anything else we have," said Baskin, who also directs the Peak Brain Tumor Center at the Houston hospital. "By inserting a virus into the tumor, then attacking that virus with medication while also firing up the patient's own , you can get a real one-two punch treatment effect, and prolonged survival."

He stressed that the treatment may not be a cure. "The [survival] numbers still stink," Baskin said. "But they're significantly better, which makes this a big advance."

Baskin and his team are slated to present their findings Sunday in Chicago at the annual meeting of the American Society of Clinical Oncology.

The initial research spanned 2006 to 2010, when the investigators inserted harmless pieces of herpes simplex viral DNA into a . That modified virus was then injected directly into cancerous tissue. The researchers picked the cold virus because it's known to spread widely and quickly in cells.

In the new clinical trial study, the 48 glioblastoma patients received the gene therapy after undergoing "aggressive" surgery aimed at reducing the tumor.

Each patient was then given an antiviral drug. The drug was designed to recognize and attack the inserted DNA fragment, and to "break open" any brain tumor cell into which the cold virus had spread.

The result, said Baskin, is that "suddenly the immune system starts killing anything that might have these proteins. So you put the Trojan horse virus in. Then, after you kill the the tumor cells explode, causing the immune system to hyper-activate without raising toxicity [to the patient]."

"It's interesting and exciting, because the improvement [in survival] is significant," Baskin said.

How significant?

Specifically, one-year survival rose from 57 percent to 67 percent; two-year survival rose from 22 percent to 35 percent; and the number of patients who lived at least three years rose from 8 percent to 19 percent, the study team found.

Overall, average survival improved by about eight months, researchers say.

"We're not saying we have a cure, of course," noted Baskin. "But we think we have something that makes a lot of sense conceptually, and is a real advance. And of course going forward we can try to get the numbers up even more by increasing the dose and finding additional targets. But even with what we have already, the improvement is big."

Balveen Kaur is a professor of neurological surgery at Ohio State University in Columbus. She said that new approaches to fight are sorely needed.

"All current FDA-approved therapies for suffer from the drawback of having a lot of side effects, which limits their use and hence efficacy," said Kaur, who is also the associate director of OSU's Medical Center at the Comprehensive Cancer Center.

However, she cautioned that "while has a lot of potential, it is important to keep in mind that the current study is a small study, with a few patients, and future randomized studies will be essential to identify if the treatment really works."

Experts also note that findings presented at medical meetings are typically considered preliminary until published in a peer-reviewed journal.

Explore further: Poliovirus study finds that less is more

More information: Find out more about glioblastomas at the American Brain Tumor Association.

Related Stories

Poliovirus study finds that less is more

June 1, 2015
A modified poliovirus therapy that is showing promising results for patients with glioblastoma brain tumors works best at a low dosage, according to the research team at Duke's Preston Robert Tisch Brain Tumor Center where ...

Immunogene therapy combined with standard treatment is safe for patients with brain tumors

August 15, 2011
A clinical trial has shown that a form of gene therapy is safe for treating a deadly form of brain cancer, even when combined with radiation therapy.

Low dose of targeted drug might improve cancer-killing virus therapy

June 16, 2014
Giving low doses of a particular targeted agent with a cancer-killing virus might improve the effectiveness of the virus as a treatment for cancer, according to a study led by researchers at The Ohio State University Comprehensive ...

Research finds no correlation between regulatory T cells and survival in glioblastoma

April 16, 2015
Using a novel methodology of epigenetic quantitative analysis, Dartmouth-Hitchcock's Norris Cotton Cancer Center's interdisciplinary team of investigators led by Camilo Fadul, MD, found no correlation between regulatory T ...

Poliovirus vaccine trial shows early promise for recurrent glioblastoma

May 21, 2013
An attack on glioblastoma brain tumor cells that uses a modified poliovirus is showing encouraging results in an early study to establish the proper dose level, researchers at Duke Cancer Institute report.

Recommended for you

Researchers find pathways that uncover insight into development of lung cancer

August 17, 2018
Lung cancer is the leading cause of preventable cancer death. A disease of complex origin, lung cancer is usually considered to result from effects of smoking and from multiple genetic variants. One of these genetic components, ...

Scientists discover new method of diagnosing cancer with malaria protein

August 17, 2018
In a spectacular new study, researchers from the University of Copenhagen have discovered a method of diagnosing a broad range of cancers at their early stages by utilising a particular malaria protein that sticks to cancer ...

Developing an on-off switch for breast cancer treatment

August 17, 2018
T-cells play an important role in the body's immune system, and one of their tasks is to find and destroy infection. However, T-cells struggle to identify solid, cancerous tumors in the body. A current cancer therapy is using ...

Pregnant? Eating broccoli sprouts may reduce child's chances of breast cancer later in life

August 16, 2018
Researchers at the University of Alabama at Birmingham have found that a plant-based diet is more effective in preventing breast cancer later in life for the child if the mother consumed broccoli while pregnant. The 2018 ...

Three scientists share $500,000 prize for work on cancer therapy

August 15, 2018
Tumors once considered untreatable have disappeared and people previously given months to live are surviving for decades thanks to new therapies emerging from the work of three scientists chosen to receive a $500,000 medical ...

PARP inhibitor improves progression-free survival in patients with advanced breast cancers

August 15, 2018
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.